Koninklijke Philips N.V.

NYSE:PHG

Medical - Devices

Healthcare
$29.81 +2.17%

+$0.57 today

Market cap
$29.11B
Beta
0.93
P/E (TTM)
23.1
EPS (TTM)
$1.02
Dividend yield
3.62%
52W Low $22.20High $33.44

Volume 1.45M

Average 1.17M

PHG Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Koninklijke Philips N.V.NYSE: PHG

Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026

Capital expenditures dips below year-ago levels

Q2 FY2026 capital expenditures of €157M (cash outflow) fell 1.3% year over year, behind the +76.2% change in trailing-twelve-month capital expenditures. Sequentially, it rose 111.6% from the prior quarter. Over 3 fiscal years it compounded at -16.8% a year.

Context

  • Capital expenditures amounted to 1.5% of revenue in FY2025, down 0.4 pp from a year earlier.
  • Capital expenditures grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -1.3% toward the trailing-twelve-month pace of +76.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-€157M+111.6% QoQ
Last fiscal yearDec 2025
-€269M-21.6% YoY
LTMJun 2026
-€382.2M+76.2% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.3%——
1 year-21.6%——
3-year CAGR-16.8%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

EUR · from the cash flow

Latest · FY2025
(269M) EUR
Year-over-year change
+21.6%

Capital Expenditures vs competitors

How PHG compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +76.2% is the 3rd highest of 10, against a peer median of +13.6%.
  • Capital expenditures amounts to 2.2% of revenue for PHG, versus a peer median of 4.7%.
PHG Competitors
Capital Expenditures for PHG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDTMedtronic plcLTM Jul 2026$1.9B USD+3.3%+9.3%5.1%
ABTAbbott LaboratoriesLTM Jun 2026$1.19B USD-47.6%+6.9%2.5%
BSXBoston Scientific CorporationLTM Jun 2026$904M USD-7.2%+12.7%4.3%
GEHCGE HealthCare Technologies Inc.LTM Jun 2026$522M USD+21.4%+15.8%2.6%
SNNSmith & Nephew plcFY2025$433M USD+13.6%+6.5%7.0%
PHGKoninklijke Philips N.V.LTM Jun 2026€382.2M EUR+76.2%-16.8%2.2%
RMDResMed Inc.LTM Jun 2026$267.46M USD+188.0%+5.3%4.7%
LIVNLivaNova PLCLTM Sep 2026$108.84M USD+83.8%+45.2%7.2%
IRMDIRadimed CorporationLTM Mar 2026$4.85M USD-59.7%+60.6%5.6%
NPCENeuroPace, Inc.LTM Mar 2026$412K USD+72.4%-18.0%0.4%
Peer median (excluding PHG) —+13.6%+9.3%4.7%

Competitors are the stored peer set for PHG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income718.64M(1.7B)(492.99M)(912.95M)895M
Depreciation & Amortization1.32B1.6B1.26B1.39B1.13B
Deferred Income Tax00000
Stock-Based Compensation0000141M
Change in Working Capital(179.66M)(1.24B)1.51B7.57M(1.33B)
Accounts Receivables0(359.43M)322.17M(1.08M)(9M)
Inventory(686.73M)(601.16M)277.85M248.79M(115M)
Accounts Payables258.85M54.65M387.04M(630.63M)0
Other Working Capital248.22M(337.36M)518.94M390.49M(1.21B)
Other Non-Cash Items64.65M1.16B35.26M1.21B330M
Operating Cash Flow1.93B(181.82M)2.31B1.7B1.16B
Capital Expenditures(469.25M)(466.63M)(371.9M)(342.9M)(269M)
Acquisitions (Net)(3.5B)(600.11M)104.87M141.7M(3M)
Purchases of Investments(146.57M)(197.58M)(149.19M)(133.05M)0
Sales of Investments203.3M81.98M51.89M61.66M0
Other Investing Activities4.02B(12.61M)134.06M27.04M(465M)
Investing Cash Flow(317.95M)(1.58B)(553.53M)(633.87M)(737M)
Debt Repayment(296.68M)1.15B(195.68M)(88.7M)448M
Common Stock Issued27.19M12.61M000
Common Stock Repurchased(1.93B)(196.53M)(715.7M)(444.57M)0
Dividends Paid(569.71M)(433M)(2.16M)(1.08M)(328M)
Other Financing Activities(2.36M)(6.31M)(3.24M)(2.16M)(13M)
Financing Cash Flow(2.77B)525.49M(916.79M)(536.52M)107M
Effect of Forex Changes(162.77M)(136.41M)(25.17M)(105.14M)(139M)
Net Change in Cash(1.33B)(1.37B)813.77M421.64M393M
Free Cash Flow1.46B(648.45M)1.94B1.35B893M

Koninklijke Philips N.V.

NYSE:PHG

Intrinsic Alpha fair value

Locked

Current Price

$29.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.